Investors Warm to Moderna’s COVID-19 Sales, Vaccine Updates

Moderna’s flurry of updates from its Vaccine Day scored well enough with investors as shares rose 6% on Tuesday. The SpikeVax™ developer raised its 2022 sales forecast for the COVID-19 vaccine by 10.5%, from $19 billion to $21 billion, citing Japan’s purchase of 70 million more…

Source: www.genengnews.com – Read more